1. Home
  2. ELE vs SPTX Comparison

ELE vs SPTX Comparison

Compare ELE & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elemental Royalty Corporation

ELE

Elemental Royalty Corporation

HOLD

Current Price

$20.43

Market Cap

1.0B

Sector

N/A

ML Signal

HOLD

Logo Seaport Therapeutics Inc. Common Stock

SPTX

Seaport Therapeutics Inc. Common Stock

N/A

Current Price

$21.29

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ELE
SPTX
Founded
N/A
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2025
2026

Fundamental Metrics

Financial Performance
Metric
ELE
SPTX
Price
$20.43
$21.29
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$32.50
N/A
AVG Volume (30 Days)
289.5K
143.6K
Earning Date
05-13-2026
N/A
Dividend Yield
0.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$109.25
N/A
Revenue Next Year
$16.14
N/A
P/E Ratio
$255.64
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.01
$17.59
52 Week High
$26.96
$28.38

Technical Indicators

Market Signals
Indicator
ELE
SPTX
Relative Strength Index (RSI) N/A 46.39
Support Level N/A $18.72
Resistance Level N/A $22.75
Average True Range (ATR) 0.00 1.85
MACD 0.00 -0.29
Stochastic Oscillator 0.00 32.11

Price Performance

Historical Comparison
ELE
SPTX

About ELE Elemental Royalty Corporation

Elemental Royalty Corp is engaged in exploration discovery, royalty generation, royalty acquisition, and strategic investments. It is the result of the strategic merger of Elemental Altus Royalties and EMX Royalty Corporation together creating a mid-tier gold-focused royalty company with the scale, diversification, and cash flow. Geographically, the company generates revenue from North America, South America, Europe, Australia and Africa.

About SPTX Seaport Therapeutics Inc. Common Stock

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

Share on Social Networks: